T-cell receptor specific for Mycobacterium tuberculosis antigens (TCR-Mtb)

T-cell receptors (TCRs) specific for Mycobacterium tuberculosis (Mtb) antigens are essential mediators of the adaptive immune response against tuberculosis. These receptors, expressed on the surface of CD4+ and CD8+ T cells, recognize Mtb-derived peptide or lipid fragments when presented by Major Histocompatibility Complex (MHC) Class I, Class II, or non-classical molecules like HLA-E and CD1. Upon binding to these antigen-presenting complexes, the TCR initiates a signaling cascade involving the CD3 complex and ZAP-70, leading to T-cell activation, proliferation, and the release of critical effector cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). In tuberculosis, these TCRs are responsible for controlling bacterial replication and maintaining the pathogen in a latent state within granulomas. However, Mtb has evolved mechanisms to evade TCR recognition, including the inhibition of antigen processing and the induction of T-cell exhaustion. Therapeutic strategies targeting these receptors include the development of novel vaccines and adoptive T-cell therapies (TCR-T), which aim to bolster the host's cellular immunity. Additionally, immune checkpoint inhibitors and host-directed therapies are being explored to enhance the functional capacity of Mtb-specific T cells in patients with drug-resistant or chronic infections.

Other names

Mycobacterium tuberculosis-specific T-cell receptorMtb-specific TCRHLA-restricted Mtb-specific T-cell receptorCD4+ T-cell receptor (MHC II restricted)CD8+ T-cell receptor (MHC I restricted)HLA-E restricted T-cell receptorCD1-restricted T-cell receptorMR1-restricted T-cell receptor

Recognition of Mycobacterium tuberculosis-derived antigens (peptides or lipids) presented by MHC Class I, Class II, or non-classical MHC molecules (e.g., HLA-E, CD1), which triggers T-cell activation, proliferation, and the release of effector cytokines (IFN-gamma, TNF-alpha) to control infection.